WeedMD Expands Starseed Medicinal Access to Atlantic Canada Alongside Leading Cannabis Physician and Advocate Dr. Julie Hildebrand
New Brunswick-based physician leads Company’s clinical expansion into the Atlantic region
WeedMD Schedules Third Quarter 2020 Conference Call for December 1st, 2020
Company financials and operational outlook to be filed after market on November 30, 2020
WeedMD’s Color Cannabis Vaporizers Make Strong Entry in Ontario
First week of shipment to Ontario Cannabis Store (OCS) sends strain-specific Color Cannabis 510 vapes to “OCS Top 5” status as availability expands to retailers and other provinces
WeedMD Issues Deferred Share Units
WeedMD announced today that in accordance with the provisions of its deferred share unit plan the Company has authorized the issuance of an aggregate of 158,026 deferred share units to certain directors of the Company as compensation for their services.
WeedMD Appoints Seasoned HR Executive to Chief People Officer
Deborah Sikkema appointed Chief People Officer to lead the Company’s newly-integrated talent, culture and organizational development initiatives
WeedMD Appoints Veteran Finance Executive to its Board of Directors
Distinguished business leader and former Deloitte partner Luciano (Lu) Cacioppo appointed as an independent director and chair of Company’s Audit Committee
WeedMD Announces Cannabis 2.0 Supply Partnership with PAX LABS®
Pods for PAX® ERA® and ERA PRO™ cannabis vaporizers to be filled and sold by Company using its terpene-rich biomass and co-marketed under Color Cannabis and Starseed brands
WeedMD to Participate in the Jefferies Virtual Cannabis Summit 2020
WeedMD announced today its participation in the Jefferies Virtual Cannabis Summit on October 7-8, 2020.
WeedMD Reports Second Quarter 2020 Financial Results and Closes $30 Million Credit Facility with LiUNA Pension Fund
Management to host conference call on Thursday, October 1st, 2020 at 10:00 a.m. Eastern Time
WeedMD Closes Definitive Agreement for $30 Million Credit Facility with LiUNA Pension Fund
Non-dilutive financing to fund continued growth and accelerate sales of Color Cannabis adult-use products and Starseed’s unique medical service offerings to payor groups and patients
WeedMD Enters into Binding Term Sheet for $30 Million Credit Facility with LiUNA Pension Fund and Changes Filing Date of Second Quarter 2020 Financials to September 30, 2020
Non-dilutive financing to fund continued growth including accelerating sales of Color Cannabis adult-use products and Starseed’s unique medical service offerings to payor groups and patients
WeedMD and Starseed Medicinal Launch Combined Medical Sales Marketplace with Expanded Cannabis Product Offerings
Medical cannabis dried flower, oils, vaporization products and softgel capsules now available to all registered patients under one simplified online sales system
WeedMD Secures Expanded Health Canada Licence to Sell All Cannabis Formats from Flagship Cultivation Facility
Fully-licensed Strathroy site approved to cultivate, produce, package and sell dried cannabis, cannabis extracts, topicals and edibles to provincial retail and medical markets
WeedMD Advances Strategic Growth Initiatives in the Adult-Use Market with New Color Cannabis Offerings
Exclusive new strain added to Color Cannabis line up; includes new vaporization and pre-roll product offerings; as well as new nitrogen-infused packaging
WeedMD Announces Investor Conference Presentations in September
Company to present at the LD 500 Virtual Conference and H.C. Wainwright & Co.’s 22nd Annual Global Investment Conference
WeedMD to File Second Quarter 2020 Financials on September 23rd
The Company will host a conference call on Thursday, September 24th, 2020, at 10 a.m. ET
WeedMD Enters into Commercial Arrangement with Fire & Flower to produce CBD Cannabis Products
Fire & Flower’s Revity CBD private label brand produced by CX Industries launches in Saskatchewan cannabis retail stores
WeedMD Grants Deferred Share Units
WeedMD announced today that in accordance with the provisions of its deferred share unit plan the Company has authorized the grant of an aggregate of 356,434 deferred share units to certain directors of the Company as compensation for their services.
WeedMD Signs Exclusive Licensing Agreement with Mary’s Medicinals for Premium Line of Wellness Products
Award-winning products to be manufactured by CX Industries in Canada starting Q4 2020, for sale across all WeedMD’s medical and adult-use channels
WeedMD Announces Resignation of Dr. Hugh Scully from Board of Directors
Dr. Scully was recently reappointed to the Board of Directors, but a personal matter has arisen which has led him to submit his resignation.